文献速递免疫规划慢病防控与筛查卫生政策与健康促进

NHANES 2003-2014 年人乳头瘤病毒(HPV)感染率随时间的地区差异

Regional variations in human papillomavirus prevalence across time in NHANES (2003-2014).
PubMed 文献 · Vaccine · 2019-06-07

该研究利用 NHANES 2003-2014 年重复横断面数据,分析 14-34 岁女性(N=6387)HPV 感染率的地区差异与时间趋势。结果显示,疫苗型 HPV 感染率在晚期上市后年份(2011-2014)较疫苗前年份(2003-2006)下降(p=0.001),且南部和中西部最高(均 8.6%),东北部最低(3.5%);下降部分归因于 HPV 疫苗接种。

要点

  • 疫苗型 HPV 感染率在 2011-2014 年较 2003-2006 年下降(p=0.001)。
  • 2011-2014 年南部和中西部疫苗型 HPV 感染率最高(均 8.6%)。
  • 随时间降低的疫苗型 HPV 感染 odds 归因于时间及更强的疫苗接种。

核心结论

  • 疫苗前与上市后年份间疫苗型 HPV 感染率存在地区差异。
  • 感染率下降至少部分归因于 HPV 疫苗接种。
  • 需要项目解决 HPV 疫苗接种的地理差异。

研究设计与样本

  • 重复横断面研究,数据来自 NHANES 2003-2014。
  • 纳入 14-34 岁提供合格阴道样本进行 HPV DNA 分型的女性(N=6387)。
  • 使用卡方和多变量 logistic 回归分析地区与疫苗接种状态和 HPV 感染率的关联。

主要发现

  • 疫苗型 HPV 感染率在疫苗前(2003-2006)与早期上市后(2007-2010)周期之间无下降(p>0.05)。
  • 疫苗型 HPV 感染率在晚期上市后年份(2011-2014)较疫苗前年份(2003-2006)下降(p=0.001)。
  • 2011-2014 年疫苗型 HPV 感染率:南部 8.6%,中西部 8.6%,西部 4.8%,东北部 3.5%。
  • 上市后调查周期中疫苗型 HPV 感染 odds 降低归因于时间,且更强归因于 HPV 疫苗接种。

临床怎么用

  • 应针对 HPV 疫苗接种率低的地区加强接种项目以缩小地理差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The consequences of low human papillomavirus (HPV) vaccination in Census regions with higher incidence of cervical cancer may contribute to continued disparities. Our purpose was to evaluate regional variations in HPV prevalence across time. METHODS: Repeated cross-sectional data from the National Health and Nutrition Examination Survey (NHANES), 2003-2014 were examined. Participants included females 14 to 34 years old who provided adequate vaginal samples for HPV DNA typing (N = 6387). Region of residence and HPV vaccination status associations with HPV prevalence were examined using chi-square and multivariable logistic regression. HPV types were grouped according to vaccine-type HPV (types 6, 11, 16, 18) and risk (high or low-risk). Time and vaccination status were included in subsequent models for post-licensure survey cycles (2007-2014) to assess their effects on observed associations. RESULTS: No decreases in vaccine-type HPV prevalence were found between the prevaccine cycles (2003-2006) and early post-licensure cycles (2007-2010, p > 0.05). Vaccine-type HPV prevalence decreased in late post-licensure years (2011-2014) compared to prevaccine years (2003-2006, p = 0.001). The highest prevalence of vaccine-type HPV occurred in the South (8.6%) and Midwest (8.6%), followed by the West (4.8%), and the Northeast (3.5%) in late post-licensure years. Lower odds of vaccine-type HPV across time in post-licensure survey cycles were found to be attributable to time, and more strongly to HPV vaccination. CONCLUSIONS: There were regional variations in vaccine-type HPV prevalence between prevaccine and post-licensure years. These decreases appeared to be at least partially attributable to HPV vaccination. Programs are needed to address geographical disparities in HPV vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hirth JM, Kuo YF, Starkey JM, et al. Regional variations in human papillomavirus prevalence across time in NHANES (2003-2014). Vaccine. 2019. PMID: 31182324. doi:10.1016/j.vaccine.2019.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。